Join to View Full Profile
Perelman Center for Advanced Medicine3400 Civic Center BlvdPhiladelphia, PA 19104
Phone+1 215-614-1850
Fax+1 215-615-3349
Dr. Martin is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
Temple University Hospital-Fox Chase Cancer CenterFellowship, Hematology and Medical Oncology, 2003 - 2006
Boston University Medical CenterResidency, Internal Medicine, 1999 - 2002
Lewis Katz School of Medicine at Temple UniversityClass of 1999
Certifications & Licensure
PA State Medical License 2003 - 2026
MA State Medical License 2002 - 2005
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2014-2017
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2014-2017
Clinical Trials
- Carboplatin, Paclitaxel, Bevacizumab, and Veliparib in Treating Patients With Newly Diagnosed Stage II-IV Ovarian Epithelial, Fallopian Tube, or Primary Peritoneal Cancer Start of enrollment: 2009 Oct 28
- Dose Escalation Safety Study of TL32711 in Adults With Refractory Solid Tumors or Lymphoma Start of enrollment: 2009 Nov 01
- Rilotumumab in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer Start of enrollment: 2010 Oct 01
Publications & Presentations
PubMed
- Approaches to optimize the benefits of immunotherapy and immunotherapy combinations across endometrial cancer types.Bradley R Corr, Kara D Romano, Michael D Toboni, Katherine C Fuh, Kathy Han
Journal of the National Cancer Institute. 2026-02-18 - 2 citationsIncidence of ESR1 gene mutations among patients with endometrioid endometrial cancer.Minyoung Jang, Christian Dagher, Stefan Gysler, Emily M Ko, Robert L Giuntoli 2nd
International Journal of Gynecological Cancer. 2026-02-01 - 7 citationsSafety and efficacy of mirvetuximab soravtansine, a folate receptor alpha (FRα)-targeting antibody-drug conjugate (ADC), in combination with pembrolizumab in patients ...Ursula A Matulonis, Ignace Vergote, Kathleen N Moore, Lainie P Martin, Cesar M Castro
Gynecologic Oncology. 2025-09-01
Journal Articles
- Phase Ib Study of Mirvetuximab Soravtansine, a Folate Receptor Alpha (FRα)-Targeting Antibody-Drug Conjugate (ADC), in Combination with Bevacizumab in Patients with Pl...David M O'Malley, Ursula A Matulonis, Michael J Birrer, Cesar M Castro, Lainie P Martin, Kathleen N Moore, Gynecologic Oncology
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
